How to manage a patient with non-ischemic cardiomyopathy (Non-Ischemic Cardiomyopathy) and recurrent heart failure admissions not responding to Guideline-Directed Medical Therapy (GDMT)?

Management of Non-Ischemic Cardiomyopathy with Recurrent Heart Failure Admissions Despite GDMT

For patients with non-ischemic cardiomyopathy and recurrent heart failure admissions despite guideline-directed medical therapy (GDMT), a comprehensive evaluation for advanced heart failure is essential, including consideration for advanced therapies such as cardiac resynchronization therapy, implantable cardioverter-defibrillator, or heart transplantation evaluation. 1

Initial Assessment

• Confirm the patient is classified as Stage D advanced heart failure, defined as "marked HF symptoms that interfere with daily life and with recurrent hospitalizations despite attempts to optimize GDMT" 1

• Evaluate current GDMT regimen to ensure all appropriate medications are prescribed at target or maximally tolerated doses:

  • Beta-blockers
  • ACE inhibitors/ARBs/ARNI
  • Mineralocorticoid receptor antagonists
  • SGLT2 inhibitors 1

• Review medication adherence, as this is a common cause of apparent treatment failure 1, 2

Diagnostic Evaluation

• Assess for potential causes of worsening heart failure:

  • Coronary artery disease requiring revascularization 1
  • Valvular heart disease, particularly mitral regurgitation 1
  • Arrhythmias, especially atrial fibrillation 1
  • Uncontrolled hypertension 1

• Perform cardiopulmonary exercise testing to quantify functional limitation and aid in selection for advanced therapies 1

• Consider invasive hemodynamic monitoring to assess filling pressures and guide therapy 1

• Evaluate for comorbidities that may exacerbate heart failure:

  • Iron deficiency (with or without anemia) 1
  • Sleep apnea 1

Therapeutic Interventions

Optimize GDMT

• Ensure all appropriate medications are at target doses or maximally tolerated doses:

  • Uptitrate in small increments with close monitoring of vital signs 1
  • Monitor renal function and electrolytes during uptitration 1
  • Consider remote medication optimization programs if available 3

• For patients with systolic dysfunction (LVEF <50%):

  • Continue guideline-directed therapy for HF with reduced EF 1
  • Consider discontinuing previously indicated negative inotropic agents (verapamil, diltiazem, disopyramide) 1

Device Therapy

• Evaluate for cardiac resynchronization therapy (CRT) if:

  • LVEF ≤35% and NYHA class II-IV symptoms
  • QRS duration ≥120 ms, especially with LBBB pattern 1

• Consider implantable cardioverter-defibrillator (ICD) if:

  • LVEF ≤35% with NYHA class II-III symptoms
  • LVEF <50% in the setting of non-ischemic cardiomyopathy 1

Advanced Therapies

• For patients with persistent NYHA class III-IV symptoms despite optimal medical and device therapy:

  • Refer for heart transplantation evaluation 1
  • Consider left ventricular assist device (LVAD) as bridge to transplantation or destination therapy 1

• Consider transcatheter edge-to-edge mitral valve repair if:

  • Severe secondary mitral regurgitation
  • LVEF 20-50%
  • LVESD <70 mm
  • Pulmonary artery systolic pressure <70 mm Hg 1

• Consider wireless pulmonary artery pressure monitoring for patients with:

  • NYHA class III symptoms
  • History of heart failure hospitalization or elevated natriuretic peptide levels 1

Rehabilitation and Lifestyle Modifications

• Cardiac rehabilitation can be beneficial to improve functional status and quality of life 4

• Emphasize regular physical activity, maintaining normal weight, healthy dietary patterns, and smoking cessation 1

Common Pitfalls and Caveats

• Clinical inertia is a significant barrier to GDMT optimization. Studies show that many patients do not receive medication adjustments despite clear indications 5, 2

• Underdosing of GDMT is common, with only 15.5% of patients achieving optimal GDMT in clinical trials 5

• Hypotension, bradycardia, renal dysfunction, and hyperkalemia are common barriers to GDMT optimization, but up to half of patients may be undertreated for unknown reasons 2

• Withdrawal of GDMT in patients with improved EF can lead to deterioration in cardiac function 1

• Patients with advanced heart failure may require more frequent visits and laboratory monitoring during dose titration 1